Navigation Links
Spherix Regains Full NASDAQ Compliance
Date:5/22/2009

ientific research company, under the name Biospherics Research. The company now leverages its scientific and technical expertise and experience through its two subsidiaries -- Biospherics Incorporated and Spherix Consulting, Inc. Biospherics is currently running a Phase 3 clinical trial to study the use of Naturlose as a treatment for Type 2 diabetes. Its Spherix Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products, and industrial chemicals and pesticides. For more information, please visit www.spherix.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of Naturlose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop Naturlose may be
'/>"/>

SOURCE Spherix Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Spherix to Exhibit at the BIO 2009 International Convention
2. Spherix Recruiting New Independent Director to Regain NASDAQ Compliance
3. Spherix Incorporated Announces the Death of A. Paul Cox, Jr., Chairman of the Board
4. Spherix Announces 2008 Financial Results
5. Spherix Reports 3rd Quarter Earnings
6. Spherix Transfers Stock Listing to Nasdaq Capital Market
7. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
8. Spherix Receives NASDAQ Bid Price Deficiency Letter
9. Spherix Reports 1st Quarter Earnings
10. Spherix Holds Annual Shareholders Meeting
11. Spherix Hires Key Employees
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... , Oct. 24, 2014  RegeneRx Biopharmaceuticals, Inc. (OTCBB: ... presented at the Fourth International Symposium on Thymosins in ... Italy.  "When thymosin beta 4 (TB4) ... into the peritoneal cavity in a rodent model of ... throughout the brain parenchyma (the functional tissue of the ...
(Date:10/22/2014)... , Oct. 22, 2014 New test innovations ... in vitro diagnostic (IVD) test industry, especially as companies ... market researcher listed more than 25 testing innovations in ... the future of IVD products. Kalorama details the new approaches ... Worldwide Market for In Vitro Diagnostic Tests , ...
(Date:10/22/2014)... The North American crystal oscillator market ... with analysis and forecast of revenue. This market was ... to reach $623.6 million by 2018, at a CAGR ... the TOC of the North American crystal oscillator market ... provided. This also provides a glimpse of the segmentation ...
(Date:10/22/2014)... San Diego, CA (PRWEB) October 22, 2014 ... laboratory balances from Sartorius, A & D Weighing, ... Sartorius CPA Semi-Micro Balance . The Sartorius ... looking for an affordable high-quality, precise, and user-friendly ... in manufacturing of laboratory equipment, their laboratory balances ...
Breaking Biology Technology:Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3
... groups have stepped forward in an attempt to prevent a ... the state, but outside investors are still in the picture. ... Credential), will meet with four prospective Wisconsin investors on May ... 19 in Green Bay. Those meetings will precede talks with ...
... Wis. - A technology that could enhance the ... avian influenza, and also be useful in vaccine development, ... will receive a Phase II Small Business Innovation Research ... for Allergy & Infectious Diseases. The grant will be ...
... Wis. - The president of the Wisconsin Economic ... to sign a bill that would remove from the books ... investment, but thus far the governor has been non-committal. , ... Legislature, and it has received another boost from James Otterstein, ...
Cached Biology Technology:Wisconsin investors will make their pitch to IPIC 2Pressure mounts for Doyle to repeal shareholder liability law 2
(Date:10/25/2014)... 22, 2014 A recent report, "Genetic Testing ... current and future genetic testing market. A comprehensive introduction ... covered in this report. On account of our analysis ... existing strengths and challenges; forecast for genetic testing has ... to grow at a CAGR of around 9% during ...
(Date:10/22/2014)... Aware, Inc. (NASDAQ: AWRE ), a ... results for its third quarter ended September 30, 2014. ... million, an increase of 40% compared to $4.3 million in ... quarter of 2014 was $4.1 million compared to $1.0 million ... the current three month period was primarily due to: i) ...
(Date:10/17/2014)... Accurate knowledge regarding Ebola is critical and pertinent for ... hazardous global outbreak and epidemic. The Journal, Disaster ... special issue, Ebola Virus and Public Health, to surround ... in this critical societal moment. , On October ... for Clinicians . The primer was prepared by Dr. ...
Breaking Biology News(10 mins):Genetic Testing Market Outlook 2018 2Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7
... study conducted by Dr. Jesus Lovera, Assistant Professor of ... colleagues has found that the herbal supplement Ginkgo biloba ... Sclerosis (MS.) Cognitive impairment affects 40-60% of people with ... executive skills. The research findings were published online ahead ...
... recently awarded $55.5 million to university consortia to ... will advance interdisciplinary nanosystems research and education in ... years, these Nanosystems ERCs, or NERCS, will advance ... issues, such as the human health and environmental ...
... announced continued support of the Colorado BioScience Association ... sciences showcase event in Colorado to be held at ... believe in the goals and community that is fostered by ... CEO of BiOptix.   "As Colorado continues to expand its ...
Cached Biology News:LSUHSC research finds ginkgo biloba doesn’t improve cognitive function in MS 2Engineering research centers awarded $55.5 million to innovate in nanoscale science and engineering 2Engineering research centers awarded $55.5 million to innovate in nanoscale science and engineering 3BiOptix Participates in Leading Life Sciences Event BioWest 2012 2
Denhardt's Solution is a mixture of blocking agents used in membrane-based hybridization protocols. The solution contains 1% Ficoll (type 400) 1% polyvinylpyrrolidone and 1% bovine serum albumin. Ste...
... innovation from Magnetofection technology, SilenceMag is ... available. Simple, rapid and easy to ... non toxic. Specifically designed for siRNA ... at very low doses of siRNA.,SilenceMag ...
... is >95%NEN Radiolabeled Ligands\n\nReceptor-related research has long ... new radiolabeled ligands selected to keep pace ... range of products and services for receptor ... state-of-the-art radioligands. If you do not find ...
Anti-WT-1 Liquid. In 10 μM PBS, 0.2 % BSA, pH 7.6. Recognizes the ~47-55 kDa Wilm's tumor protein in Wilm's tumor tissue. ...
Biology Products: